AAVantgarde Reports Eye Disease Gene Therapy Data at EURetina 2026
AAVantgarde shared updated clinical and preclinical findings for two gene therapies targeting rare inherited retinal diseases at a major European ophthalmology conference.
AAVantgarde presented updated results from its LUCE-1 Phase 1/2 clinical study evaluating AAVB-081 in patients with Usher syndrome type 1B at the EURetina 2026 conference, a leading European forum for retinal disease specialists. The data were described as encouraging, signaling continued progress in the company's efforts to develop gene-based treatments for rare, vision-threatening conditions.
Alongside the clinical update, AAVantgarde also disclosed preclinical data supporting the eventual clinical development of AAVB-039, a separate gene therapy candidate targeting Stargardt disease. Stargardt disease is among the most common inherited forms of macular degeneration, typically causing progressive central vision loss beginning in childhood or early adulthood. Usher syndrome type 1B is a severe genetic disorder combining profound hearing loss with progressive retinal degeneration.
Read more The General Insurance Brings Street Fighter Bonus Car to Life →
The simultaneous presentation of data across two distinct programs at a major scientific conference suggests AAVantgarde is actively advancing a pipeline aimed at multiple inherited retinal dystrophies. The move to translate AAVB-039 from preclinical work toward clinical stages would represent a meaningful pipeline expansion for the company if regulatory steps proceed as planned.
Both conditions currently lack approved disease-modifying treatments, placing gene therapy developers under close scrutiny from patient advocacy groups, clinicians, and investors watching for meaningful efficacy and safety signals in early-stage trials.
Continue reading at GlobeNewswire - Industry News on Financial Services.
